Advances and challenges of conversion therapy and neoadjuvant therapy in hepatocellular carcinoma
10.3760/cma.j.cn115610-20230105-00007
- VernacularTitle:肝细胞癌转化和新辅助治疗的进展与挑战
- Author:
Yongyi ZENG
1
;
Kongying LIN
;
Qingjing CHEN
Author Information
1. 福建医科大学孟超肝胆医院肝胆外科，福建 350001
- Keywords:
Liver neoplasms;
Surgical resection;
Conversion therapy;
Neoadjuvant therapy;
Comprehensive therapy
- From:
Chinese Journal of Digestive Surgery
2023;22(2):195-201
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is characterized by a low resection rate and a high postoperative recurrence rate. Conversion therapy and neoadjuvant therapy are effective stra-tegies to improve the long-term prognosis of patients with HCC. With the clinical application of new technologies and methods and the continuous emergence of new anti-tumor drugs, the conversion therapy and neoadjuvant therapy of HCC have ushered in an unprecedented development. At the same time, they are also facing many new challenges. Based on our own clinical experience and the latest progress in conversion therapy and neoadjuvant therapy of HCC, the authors classify and summarize the selection of treatment strategies and the challenges faced in HCC conversion therapy and neoadjuvant therapy.
